Apellis Pharmaceuticals: Looking For Entry Around Crucial Q3 Earnings (NASDAQ:APLS)

Money on the edge

PM Images

Apellis Pharmaceuticals (NASDAQ:APLS), a standout player in the biotech sector, distinguishes itself with its novel C3 inhibitor technology, including their flagship compound, pegcetacoplan which has been branded into EMPAVELI (systemic) and SYVOVRE (intravitreal). Apellis has aimed pegcetacoplan to take on treating Paroxysmal Nocturnal Hemoglobinuria (PNH) and

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *